Index RUT
P/E 11.29
EPS (ttm) 1.29
Insider Own 3.33%
Shs Outstand 46.48M
Perf Week 10.83%
Market Cap 670.27M
Forward P/E 4.81
EPS next Y 3.02
Insider Trans -0.33%
Shs Float 44.59M
Perf Month 4.91%
Income 63.59M
PEG 1.05
EPS next Q 0.72
Inst Own 114.03%
Short Float 13.56%
Perf Quarter -49.28%
Sales 690.31M
P/S 0.97
EPS this Y 7.35%
Inst Trans 2.22%
Short Ratio 4.32
Perf Half Y -50.39%
Book/sh 19.07
P/B 0.76
EPS next Y 0.15%
ROA 3.99%
Short Interest 6.05M
Perf Year -57.87%
Cash/sh 8.76
P/C 1.66
EPS next 5Y 10.80%
ROE 7.54%
52W Range 11.16 - 35.95
Perf YTD -56.94%
Dividend Est. -
P/FCF 3.63
EPS past 5Y -
ROI 4.19%
52W High -59.58%
Beta 0.84
Dividend TTM -
Quick Ratio 5.70
Sales past 5Y 15.46%
Gross Margin 65.75%
52W Low 30.15%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 6.82
EPS Y/Y TTM 1451.33%
Oper. Margin 14.65%
RSI (14) 47.02
Volatility 6.52% 4.87%
Employees 712
Debt/Eq 0.74
Sales Y/Y TTM 3.15%
Profit Margin 9.21%
Recom 2.78
Target Price 18.00
Option/Short Yes / Yes
LT Debt/Eq 0.73
EPS Q/Q -21.44%
Payout 0.00%
Rel Volume 3.07
Prev Close 14.69
Sales Surprise 2.47%
EPS Surprise 27.34%
Sales Q/Q 5.05%
Earnings Jul 30 AMC
Avg Volume 1.40M
Price 14.53
SMA20 2.22%
SMA50 -13.25%
SMA200 -44.60%
Trades
Volume 4,300,717
Change -1.09%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Downgrade
Truist
Buy → Sell
$30 → $8
Aug-12-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$37 → $14
Aug-12-24 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-12-24 Downgrade
Piper Sandler
Overweight → Neutral
$42 → $11
Aug-12-24 Downgrade
JP Morgan
Overweight → Underweight
$45 → $10
Jul-03-24 Downgrade
Barclays
Overweight → Equal Weight
$38 → $25
Mar-07-24 Resumed
JP Morgan
Overweight
$80 → $45
Dec-20-23 Initiated
Raymond James
Outperform
$42
Aug-03-23 Upgrade
TD Cowen
Market Perform → Outperform
$50
Jan-31-23 Resumed
Wedbush
Outperform
$88 → $60
Oct-21-22 Resumed
Jefferies
Buy
$66
Jan-03-22 Resumed
JP Morgan
Overweight
$75 → $83
Jul-26-21 Upgrade
JP Morgan
Neutral → Overweight
$75
Apr-21-21 Resumed
JP Morgan
Neutral
$70
Apr-09-21 Initiated
Berenberg
Buy
$93
Apr-07-21 Resumed
RBC Capital Mkts
Outperform
$86
Feb-11-21 Downgrade
Northland Capital
Outperform → Market Perform
$72 → $75
Jan-21-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$75
Sep-21-20 Upgrade
Northland Capital
Market Perform → Outperform
$58 → $67
Jul-06-20 Reiterated
Needham
Buy
$52 → $64
Show Previous Ratings
Sep-09-24 04:00PM
Aug-09-24 03:21PM
Jul-31-24 10:49AM
Jul-30-24 08:58PM
04:14PM
(Associated Press Finance)
04:00PM
Loading…
04:00PM
Jul-29-24 06:00AM
Jul-23-24 08:00AM
03:52AM
Jul-17-24 09:50AM
Jul-12-24 10:41AM
Jul-10-24 04:19PM
Jun-14-24 02:41AM
Jun-06-24 11:31AM
May-30-24 08:00AM
07:00AM
Loading…
May-10-24 07:00AM
May-08-24 04:05PM
11:35AM
09:33AM
03:47AM
May-07-24 09:01PM
06:03PM
05:30PM
04:13PM
(Associated Press Finance)
04:00PM
08:00AM
Apr-30-24 08:00AM
Apr-04-24 11:33AM
Apr-02-24 08:00AM
Mar-14-24 08:23AM
07:00AM
Loading…
Mar-13-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Mar-01-24 08:38AM
06:05AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
(Associated Press Finance)
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
08:23AM
(Associated Press Finance)
08:00AM
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
(Thomson Reuters StreetEvents) -7.17%
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Mar-22-23 08:00AM
Mar-09-23 09:17AM
Mar-08-23 08:00AM
Feb-28-23 11:39PM
(Thomson Reuters StreetEvents)
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:00AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GAUGLER DARYL Chief Operating Officer Sep 13 '24 Sale 12.86 500 6,430 115,700 Sep 13 08:29 PM GAUGLER DARYL Officer Sep 13 '24 Proposed Sale 12.86 500 6,430 Sep 13 10:17 AM BIGAL MARCELO Director Aug 16 '24 Buy 13.25 1,512 20,034 10,142 Aug 19 08:25 AM Brege Laura Director Aug 16 '24 Buy 12.81 1,000 12,810 17,552 Aug 19 08:25 AM YANG MICHAEL J. Director Aug 14 '24 Buy 12.90 2,000 25,800 7,230 Aug 14 04:35 PM Lee Frank D. Chief Executive Officer Aug 12 '24 Buy 12.10 8,264 99,994 107,784 Aug 13 04:55 PM Froimson Mark Director Aug 12 '24 Buy 11.58 1,400 16,212 14,473 Aug 12 08:33 PM BIGAL MARCELO Director Aug 12 '24 Buy 12.01 3,400 40,834 8,630 Aug 12 08:33 PM SLONIN JONATHAN Chief Medical Officer Aug 02 '24 Sale 20.05 945 18,947 94,307 Aug 02 06:00 PM SLONIN JONATHAN Officer Aug 02 '24 Proposed Sale 20.05 945 18,947 Aug 02 10:09 AM SLONIN JONATHAN Chief Medical Officer Jul 02 '24 Sale 28.25 2,836 80,117 95,557 Jul 03 06:52 PM RIKER LAUREN Senior Vice President, Finance Jun 12 '24 Sale 28.72 3,970 114,018 38,075 Jun 13 06:15 PM SLONIN JONATHAN Chief Medical Officer Jun 11 '24 Sale 28.57 5,012 143,193 44,569 Jun 13 06:15 PM GAUGLER DARYL Chief Operating Officer Jun 13 '24 Sale 28.38 1,000 28,380 116,040 Jun 13 06:13 PM HASTINGS PAUL J Director Jun 13 '24 Sale 28.38 880 24,974 12,724 Jun 13 06:13 PM WILLIAMS KRISTEN Chief Administrative Officer Jun 13 '24 Sale 28.38 7,452 211,488 102,912 Jun 13 06:12 PM PACE GARY W Director Mar 08 '24 Sale 30.60 90,000 2,754,000 22,127 Mar 08 05:33 PM PACE GARY W Director Mar 07 '24 Sale 30.81 28,257 870,598 112,127 Mar 08 05:33 PM PACE GARY W Director Mar 06 '24 Sale 29.67 1,066 31,628 140,384 Mar 08 05:33 PM
Index RUT
P/E 92.61
EPS (ttm) 0.18
Insider Own 0.76%
Shs Outstand 164.65M
Perf Week 1.29%
Market Cap 2.74B
Forward P/E 19.10
EPS next Y 0.87
Insider Trans -9.59%
Shs Float 164.62M
Perf Month 3.77%
Income 30.57M
PEG -
EPS next Q 0.13
Inst Own 97.47%
Short Float 6.24%
Perf Quarter 8.04%
Sales 890.53M
P/S 3.08
EPS this Y 250.04%
Inst Trans 0.91%
Short Ratio 6.06
Perf Half Y -10.21%
Book/sh 3.12
P/B 5.31
EPS next Y 55.89%
ROA 3.93%
Short Interest 10.27M
Perf Year -30.52%
Cash/sh 3.02
P/C 5.47
EPS next 5Y -
ROE 6.70%
52W Range 14.55 - 32.59
Perf YTD -47.21%
Dividend Est. -
P/FCF 34.07
EPS past 5Y 28.03%
ROI 5.42%
52W High -49.28%
Beta 0.39
Dividend TTM -
Quick Ratio 1.95
Sales past 5Y 27.73%
Gross Margin 91.72%
52W Low 13.61%
ATR (14) 0.56
Dividend Ex-Date -
Current Ratio 2.16
EPS Y/Y TTM 126.79%
Oper. Margin 2.56%
RSI (14) 54.11
Volatility 2.76% 3.33%
Employees 598
Debt/Eq 0.11
Sales Y/Y TTM 61.65%
Profit Margin 3.43%
Recom 1.79
Target Price 25.11
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 2854.41%
Payout -
Rel Volume 0.90
Prev Close 16.42
Sales Surprise 2.55%
EPS Surprise 12.55%
Sales Q/Q 46.44%
Earnings Aug 06 AMC
Avg Volume 1.69M
Price 16.53
SMA20 2.62%
SMA50 -1.95%
SMA200 -17.28%
Trades
Volume 1,526,042
Change 0.67%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-07-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$28 → $20
Jun-27-24 Initiated
BMO Capital Markets
Outperform
$31
Mar-12-24 Reiterated
Needham
Buy
$36 → $32
Mar-12-24 Downgrade
Mizuho
Buy → Neutral
$39 → $25
Jan-30-24 Initiated
Robert W. Baird
Outperform
$40
Jan-24-24 Upgrade
Needham
Hold → Buy
$37
Dec-19-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$31 → $40
Dec-14-23 Downgrade
Deutsche Bank
Buy → Hold
$25
Dec-13-23 Initiated
Citigroup
Buy
$38
Dec-12-23 Initiated
Deutsche Bank
Buy
$25
Nov-06-23 Upgrade
Mizuho
Neutral → Buy
$20 → $35
Oct-17-23 Initiated
UBS
Buy
$33
Oct-10-23 Upgrade
JP Morgan
Neutral → Overweight
$29 → $32
Jan-03-23 Upgrade
Guggenheim
Neutral → Buy
$22
Nov-04-22 Downgrade
Goldman
Neutral → Sell
$15 → $12
Nov-01-22 Initiated
Loop Capital
Hold
$17
Aug-08-22 Downgrade
Citigroup
Buy → Neutral
$19 → $15
Aug-05-22 Downgrade
Citigroup
Buy → Neutral
$19 → $15
Jun-21-22 Downgrade
Jefferies
Buy → Underperform
$25 → $10
Jun-16-22 Upgrade
Jefferies
Hold → Buy
$25
Show Previous Ratings
Aug-29-24 08:30AM
Aug-28-24 04:05PM
Aug-14-24 08:04AM
Aug-07-24 04:30PM
04:14PM
(Investor's Business Daily)
08:16AM
Loading…
08:16AM
Aug-06-24 05:45PM
04:42PM
(Associated Press Finance)
04:05PM
Jul-30-24 10:01AM
Jul-24-24 04:05PM
Jul-18-24 09:04AM
Jul-16-24 10:28AM
Jun-21-24 12:24PM
10:53AM
09:04AM
Loading…
Jun-18-24 09:04AM
Jun-07-24 11:30AM
May-29-24 10:01AM
May-17-24 04:05PM
May-15-24 09:05AM
May-10-24 01:15PM
11:20AM
10:01AM
May-09-24 04:58PM
03:29PM
11:07AM
05:59AM
03:37AM
May-08-24 08:57PM
05:15PM
04:15PM
Loading…
04:15PM
(Associated Press Finance)
04:05PM
May-04-24 02:27AM
May-01-24 10:01AM
Apr-30-24 12:17PM
Apr-29-24 04:16PM
Apr-24-24 04:05PM
Apr-22-24 09:04AM
Apr-20-24 09:15AM
Apr-19-24 04:05PM
Apr-17-24 04:05PM
Apr-11-24 02:10PM
Apr-10-24 01:28AM
Apr-02-24 04:05PM
Apr-01-24 04:05PM
Mar-28-24 11:30AM
02:00AM
Mar-20-24 01:31PM
Mar-15-24 04:05PM
Mar-14-24 06:49PM
Mar-13-24 04:05PM
Mar-12-24 04:08PM
(Investor's Business Daily) -17.20%
03:05PM
11:06AM
09:30AM
07:43AM
Mar-11-24 04:46PM
04:13PM
04:05PM
Feb-29-24 09:05AM
08:44AM
Feb-28-24 04:05PM
(Investor's Business Daily) -9.92%
09:12AM
Feb-27-24 05:20PM
04:56PM
04:27PM
(Associated Press Finance)
04:05PM
Feb-22-24 08:16PM
Feb-21-24 04:05PM
Feb-20-24 10:00AM
Feb-13-24 04:05PM
Feb-08-24 01:15PM
Jan-30-24 08:48PM
05:00PM
Jan-26-24 05:31PM
Jan-25-24 08:42AM
Jan-19-24 04:05PM
Jan-18-24 04:05PM
Jan-12-24 05:02PM
Dec-21-23 04:05PM
Dec-18-23 04:05PM
Dec-13-23 09:24PM
04:14PM
(Investor's Business Daily)
01:41PM
Nov-30-23 09:05AM
Nov-27-23 09:05AM
Nov-21-23 11:03PM
05:00PM
Nov-17-23 09:40AM
Nov-16-23 08:42AM
Nov-14-23 04:12PM
Nov-08-23 05:24PM
Nov-04-23 01:10PM
Nov-02-23 06:51PM
04:37PM
(Associated Press Finance)
04:05PM
Oct-31-23 04:05PM
Oct-26-23 10:02AM
Oct-23-23 09:05AM
Oct-19-23 04:05PM
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Aug 19 '24 Sale 15.28 9,733 148,720 43,735 Aug 20 06:46 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Aug 19 '24 Sale 15.28 9,534 145,680 52,177 Aug 20 06:43 PM DAVIS STEPHEN CEO Aug 19 '24 Sale 15.28 31,747 485,094 186,555 Aug 20 06:40 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Jun 10 '24 Sale 14.79 975 14,420 34,564 Jun 11 06:00 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER May 02 '24 Sale 16.94 3,503 59,341 32,053 May 03 06:00 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL May 02 '24 Sale 16.94 3,477 58,900 42,133 May 03 06:00 PM Kihara James PRINCIPAL ACCOUNTING OFFICER May 02 '24 Sale 16.94 1,326 22,462 14,370 May 03 06:00 PM DAVIS STEPHEN CEO May 02 '24 Sale 16.94 11,427 193,573 155,231 May 03 06:00 PM DAVIS STEPHEN CEO Apr 08 '24 Sale 17.87 26,574 474,877 144,267 Apr 09 06:00 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Apr 08 '24 Sale 17.87 2,568 45,890 38,796 Apr 09 06:00 PM Kihara James PRINCIPAL ACCOUNTING OFFICER Apr 08 '24 Sale 17.87 1,790 31,987 13,100 Apr 09 06:00 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Apr 08 '24 Sale 17.87 2,716 48,535 28,742 Apr 09 06:00 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Mar 27 '24 Sale 17.90 5,140 92,006 36,340 Mar 27 08:00 PM DAVIS STEPHEN CEO Mar 27 '24 Sale 17.90 17,714 317,081 118,842 Mar 27 07:58 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Mar 27 '24 Sale 17.90 5,434 97,269 26,183 Mar 27 07:57 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Feb 26 '24 Sale 24.67 772 19,045 21,067 Feb 27 06:13 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Feb 26 '24 Sale 24.67 624 15,394 31,432 Feb 27 06:10 PM Kihara James PRINCIPAL ACCOUNTING OFFICER Feb 26 '24 Sale 24.67 474 11,694 11,391 Feb 27 06:07 PM DAVIS STEPHEN CEO Feb 26 '24 Sale 24.67 5,577 137,585 101,890 Feb 27 06:02 PM DAVIS STEPHEN CEO Jan 08 '24 Sale 29.96 3,732 111,811 96,521 Jan 09 06:00 PM Teehan Brendan EVP, COO, Head of Commercial Jan 08 '24 Sale 29.96 731 21,901 30,949 Jan 09 06:00 PM KIM AUSTIN D. EVP,General Counsel, Secretary Jan 08 '24 Sale 29.96 590 17,676 46,901 Jan 09 06:00 PM Kihara James Principal Accounting Officer Dec 15 '23 Sale 28.30 2,000 56,600 11,025 Dec 15 07:37 PM Teehan Brendan EVP, COO, Head of Commercial Nov 20 '23 Sale 22.64 4,960 112,294 30,393 Nov 21 06:00 PM Schneyer Mark C. EVP, Chief Financial Officer Nov 20 '23 Sale 22.64 5,108 115,645 20,486 Nov 21 06:00 PM Kihara James Principal Accounting Officer Nov 20 '23 Sale 22.64 1,985 44,940 13,025 Nov 21 06:00 PM KIM AUSTIN D. EVP,General Counsel, Secretary Oct 06 '23 Sale 21.96 16,369 359,463 45,857 Oct 06 10:00 PM DAVIS STEPHEN CEO Oct 06 '23 Sale 21.96 51,563 1,132,323 89,131 Oct 06 09:59 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite